Gyre Therapeutics, Inc. Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)
Gyre Therapeutics, Inc. (GYRE) reported Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) of -$91.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-09.
Discontinued › Income Statement › Other Income
us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2016-03-09
- Gyre Therapeutics, Inc. fair value, liability, recurring basis, still held, unrealized gain (loss) for the quarter ending 2015-12-31 was $0.00.
- Gyre Therapeutics, Inc. fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2015 was -$91.00K.
- Gyre Therapeutics, Inc. fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2014 was -$354.00K.
| Period end | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month |
|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | -$91.00K 10-K · filed 2016-03-09 | |
| 2015-09-30 | -$91.00K 10-Q · filed 2015-11-05 | ||
| 2014-12-31 | -$354.00K 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |